180 Wealth Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

180 Wealth Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-2,833	Closed	-$238K	–	448
2024 Q2	$238K	Sell	2,833 -60	-2%	-$5K	0.04%	365
2024 Q1	$253K	Sell	2,893 -137	-5%	-$12.3K	0.05%	330
2023 Q4	$297K	Sell	3,030 -187	-6%	-$16.5K	0.06%	279
2023 Q3	$285K	Buy	3,217 +222	+7%	+$19.8K	0.06%	271
2023 Q2	$257K	Buy	2,995 +98	+3%	+$9.22K	0.06%	282
2023 Q1	$282K	Buy	+2,897	New	+$300K	0.07%	273
2021 Q4	–	Sell	-5,450	Closed	-$414K	–	389
2021 Q3	$414K	Buy	5,450 +448	+9%	+$35.3K	0.09%	216
2021 Q2	$385K	Buy	5,002 +1,157	+30%	+$91.7K	0.09%	223
2021 Q1	$300K	Buy	+3,845	New	+$314K	0.07%	249

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

EIM

Elliott Investment Management West Palm Beach, Florida $20.1B AUM 60.76% 1-Year Est. Return

180 Wealth Advisors's BMRN Position: Q3 2024 in Review

180 Wealth Advisors sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2024, closing a stake of 2,833 shares — an estimated $238K sold.

180 Wealth Advisors first reported a position in BMRN in Q1 2021 and held it in 9 quarters. The position peaked at $414K in Q3 2021. 553 funds tracked by Wall St. Rank hold BMRN as of Q3 2024.

180 Wealth Advisors reported no remaining BioMarin Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
180 Wealth Advisors sold 2,833 BioMarin Pharmaceuticals shares in Q3 2024, an estimated $238K.
180 Wealth Advisors first reported a position in BioMarin Pharmaceuticals in Q1 2021 and held it in 9 quarters.
180 Wealth Advisors's BioMarin Pharmaceuticals position peaked at $414K in Q3 2021.
553 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2024.

Based on 180 Wealth Advisors's 13F filing for Q3 2024, filed 1 Nov 2024.